MedTrace Logo

Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling

NCT01964794 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-10-07

No results posted yet for this study

Summary

Clinically relevant biomarkers for warfarin identified in this study will provide crucial leads for subsequent studies to assess their predictive value during anticoagulant therapy. This knowledge will aid stratifying risk among patients to improve therapeutic outcomes and decrease adverse drug events and associated health care costs. Collectively, these efforts will provide a critical foundation for future research using a metabolite biomarker strategy in a clinical setting to revolutionize warfarin therapy. Through its application, a real-time assessment of warfarin metabolism for each patient could lead to a truly personalized dosing strategy and improve patient safety for this life-saving drug.

Conditions

  • Stable Target INR

Sponsors & Collaborators

  • Central Arkansas Veterans Healthcare System

    collaborator FED

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Grover P Miller, PhD · University of Arkansas

  • Eugene Smith, III, MD · Dentral Arkansas Veterans Healthcare System

Eligibility

Min Age
60 Years
Max Age
69 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01964794 on ClinicalTrials.gov